The state of drug development in Australia: a case study

After Market
28/05/2024 28 min Episodio 18
The state of drug development in Australia: a case study

Listen "The state of drug development in Australia: a case study"

Descargar episodio Ver en sitio original

Episode Synopsis

Amplia Therapeutics Ltd CEO and managing director Dr Chris Burns has had a long career in drug development, including discovering only the second Australian drug to receive US FDA approval. He has plenty of advice to share for Australian-based researchers and domestically developed biotech assets. Proactive's Susanna Nelson chats to him about the current state of clinical research and commercial drug development in Australia.

More episodes of the podcast After Market

ASX companies turn to OTC Markets for dual listing 04/06/2025
Safer chemotherapy? Race Oncology’s new drug heads to trials 28/03/2025
Australian Vanadium reinforces potential for long-lasting, high-grade vanadium and battery metal project 14/03/2024
Carbon capture and storage: An essential part of the circular economy 13/02/2024
Artemis Resources is chasing gold, copper and lithium in the Pilbara 05/01/2024
How does Australia get the best out of its relationship with China? 04/12/2023
Provaris an early mover on green hydrogen supply chain in Europe 17/11/2023
Moving clinical trials out of the hospital and into general practice 07/11/2023
Imugene forges ahead with VAXINIA trial targeting solid tumours 03/11/2023
Building a diverse portfolio during economic uncertainty 02/10/2023
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA